1. Introduction {#sec1}
===============

*Isatis indigotica* Fort. (Cruciferae) is a widely cultivated medicinal plant. The dried leaves and roots of this plant, named "da qing ye" and "ban lan gen" in Chinese, respectively, are used in traditional Chinese medicines for the treatment of influenza and other infections[@bib1]. Diverse bioactive constituents have been reported from ethanol or methanol extracts of the *I. indigotica* leaves and roots[@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25]. However, few works were done on the chemical constituents of decoctions of the two herbal medicines[@bib7], [@bib13], [@bib14], [@bib16], [@bib18], [@bib24] though the decoctions are practically applied in traditional Chinese medicine. Therefore, the aqueous extracts of "ban lan gen" and "da qing ye" were successively investigated as part of our program to systematically assess the chemical diversity and pharmacological activity of traditional Chinese medicines focusing on the minor components[@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36], [@bib37], [@bib38], [@bib39]. From the "ban lan gen" extract, 57 new alkaloids including 22 indole and bisindole alkaloid glycosides were isolated, and some of them showed antiviral activity[@bib40], [@bib41], [@bib42], [@bib43], [@bib44], [@bib45], [@bib46], [@bib47], [@bib48], [@bib49], [@bib50], [@bib51], [@bib52], [@bib53], [@bib54], [@bib55]. Previously we reported two pairs of unusual scalemic enantiomers isatidifoliumindolinones A−D from the "da qing ye" extract[@bib56], this paper deals with isolation, structural elucidation, biosynthetic postulation, and biological activity of seven unusual indole alkaloid glycosides (**1**--**7**), including three pairs of epimers named isatidifoliumosides/epiisatidifoliumosides A (**1**/**2**), B (**3**/**4**), and C (**5**/**6**), respectively, and an isomer named isatidifoliumoside D (**7**) ([Fig. 1](#fig1){ref-type="fig"}). The new isolates contain a 1′-(4″-hydroxy-3″,5″-dimethoxyphenyl)ethyl moiety at different positions (N-1, C-2, or C-3) of the indole nucleus, biogenetically associating to isatidifoliumindolinones A--D[@bib56]. Analysis of specific rotations \[*α*\]~D~ and Cotton effects (CEs) of **1**--**7** resulted in preliminary roles for assignment of location and configuration of the *β*-glycopyranosyloxy and 1′-(phenyl)ethyl units in this group of indole alkaloids. Especially, **5** and **6** are the first indole alkaloid *β*-[d]{.smallcaps}-allopyranosides from nature, while the mixture of **5** and **6** (3:2) showed antiviral activity against influenza virus H1N1 PR8, which represents the first bioactive indole glycosides supporting clinic application of the herbal medicine.Figure 1The structures of compounds **1**--**7**.Figure 1

2. Results and discussion {#sec2}
=========================

Compound **1** was isolated as a white amorphous powder with $\left\lbrack \alpha \right\rbrack_{\text{D}}^{20}$ --23.7 (*c* 0.1, MeOH). The IR spectrum of **1** exhibited absorption bands assignable to hydroxy (3303 cm^−1^) and aromatic ring (1613, 1519, and 1460 cm^−1^) functional groups. Its molecular formula of C~24~H~29~NO~9~ was determined by HR-ESI-MS combined with the NMR spectroscopic data ([Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}). The NMR spectrum of **1** in CD~3~OD showed resonances attributable to two *ortho*-disubstituted benzene rings at *δ*~H~ 7.69 (brd, *J* = 7.8 Hz, H-4), 6.97 (dt, *J* = 7.8, 1.2 Hz, H-5), 7.06 (ddd, *J* = 8.4, 7.8, 1.2 Hz, H-6), and 7.25 (brd, *J* = 8.4 Hz, H-7); a 1′,1′-disubstituted ethyl unit at *δ*~H~ 5.60 (q, *J* = 7.2 Hz, H-1′) and 1.84 (d, *J* = 7.2 Hz, H~3~-2′); a 4″-hydroxy-3″,5″-dimethoxyphenyl at *δ*~H~ 3.73 (s, OCH~3~-3″,5″) and 6.46 (s, H-2″/6″); and a trisubstituted double bond at *δ*~H~ 7.31 (s, H-2). It also displayed diagnostic resonances for a *β*-glucopyranosyl moiety ([Table 1](#tbl1){ref-type="table"}). The ^13^C NMR and DEPT spectra showed carbon resonances corresponding to the above units ([Table 2](#tbl2){ref-type="table"}). The presence of the *β*-glucopyranosyl unit was confirmed by enzymatic hydrolysis of **1** with snailase. The sugar isolated from the hydrolysate exhibited retention factor (*R*~f~) on TLC, specific rotation {$\left\lbrack \alpha \right\rbrack_{\text{D}}^{20}$ +40.2 (*c* 0.08, H~2~O)}, and ^1^H NMR spectroscopic data identical to those of an authentic glucopyranose (see [Experimental Section](#sec4){ref-type="sec"} and [Supporting Information Figs. S120 and S124](#appsec1){ref-type="fn"}).Table 1^1^H NMR spectroscopic data for compounds **1--7** in CD~3~OD[a](#tbl1fna){ref-type="table-fn"}.Table 1No.**1234567**27.31 s7.31 s6.99 s47.69 brd (7.8)7.69 brd (7.8)7.70 brd (7.8)7.74 brd (7.8)7.72 brd (7.8)7.76 brd (7.8)56.97 dt (7.8, 1.2)6.97 dt (7.8, 1.2)6.94 dt (7.8, 1.2)6.94 dt (7.8, 1.2)6.94 dt (7.8, 1.2)6.95 dt (7.8, 1.2)6.62 brd (7.2)67.06 ddd (8.4, 7.8, 1.2)7.07 ddd (8.4, 7.8, 1.2)7.00 dt (7.8, 1.2)7.00 ddd (8.4, 7.8, 1.2)7.00 dt (7.8, 1.2)7.00 dt (7.8, 1.2)6.94 t (7.2)77.25 brd (8.4)7.25 brd (8.4)7.22 brd (7.8)7.21 brd (8.4)7.21 d (7.8)7.21 brd (7.8)6.97 dd (7.2, 1.2)1′5.60 q (7.2)5.61 q (7.2)4.74 q (7.2)4.73 q (7.2)4.74 q (7.2)4.74 q (7.8)4.87 q (7.2)2′1.84 d (7.2)1.84 d (7.2)1.68 d (7.2)1.65 d (7.2)1.67 d (7.2)1.66 d (7.8)1.59 d (7.2)2″6.46 s6.45s6.71 s6.64 s6.68 s6.64 s6.56 s6″6.46 s6.45 s6.71 s6.64 s6.68 s6.64 s6.56 s1‴4.72 d (7.2)4.71 d (7.8)4.62 d (8.4)4.66 d (7.8)5.05 d (7.8)5.04 d (8.4)5.06 d (7.8)2‴3.50 dd (9.0, 7.2)3.50 dd (7.8, 9.0)3.53 dd (9.0, 8.4)3.50 dd (9.0, 7.8)3.65 dd (7.8,3.0)3.63 dd (8.4,3.0)3.58 dd (9.0, 7.8)3‴3.44 t (9.0)3.43 t (9.0)3.40 t (9.0)3.41 t (9.0)4.17 t (3.0)4.15 t (3.0)3.46 t (9.0)4‴3.39 t (9.0)3.38 t (9.0)3.47 t (9.0)3.46 t (9.0)3.67 dd (9.6,3.0)3.66 dd (9.6,3.0)3.28 t (9.0)5‴3.36 m3.35 m3.14 m3.16 m3.62 m3.61 m3.41 m6‴a3.89 dd (12.0, 2.4)3.89 dd (12.0, 2.4)3.82 dd (11.4, 1.8)3.66 m3.83 dd (11.4, 2.4)3.67 m3.83 dd (12.0, 2.4)6‴b3.70 dd (12.0, 5.4)3.70 dd (12.0, 5.4)3.73 dd (11.4, 4.8)3.66 m3.74 dd (11.4, 4.8)3.67 m3.60 dd (12.0, 6.0)3″,5″-OCH~3~3.73 s3.73 s3.80 s3.79 s3.80 s3.79 s3.75 s[^1]Table 2^13^C NMR spectroscopic data for compounds **1**--**7** in CD~3~OD[a](#tbl2fna){ref-type="table-fn"}.Table 2No.**1234567**2113.1112.9133.7132.9133.6132.8121.63138.7138.8133.0133.8133.1133.9122.23a122.3122.2122.8122.7122.7122.8118.64119.0119.0118.6118.7118.7118.8153.55119.8119.8119.7119.7119.6119.6103.46122.9122.9121.9122.0121.9121.9123.07111.1111.0111.9111.9111.9111.9106.77a135.1135.1134.7134.6134.7134.6140.21′56.055.935.635.735.535.638.22′22.022.020.721.020.620.924.21″135.4135.4137.4137.2137.2137.2141.52″104.5104.5105.9106.1105.9106.1106.03″149.3149.3149.1149.1149.1149.1148.84″135.8135.8134.8134.9134.8134.9134.05″149.3149.3149.1149.1149.1149.1148.86″104.5104.5105.9106.1105.9106.1106.01‴105.9105.9107.4107.7105.0105.3101.62‴75.175.175.475.472.672.675.23‴78.178.178.278.273.273.478.74‴71.671.771.571.468.868.771.65‴78.278.377.977.975.475.478.16‴62.762.762.662.563.162.962.73″,5″-OCH~3~56.856.756.856.856.856.856.8[^2]

As compared with those of the previously reported compounds from *I. indigotica*[@bib40], [@bib41], [@bib42], [@bib43], [@bib44], [@bib45], [@bib46], [@bib47], [@bib48], [@bib49], [@bib50], [@bib51], [@bib52], [@bib53], [@bib54], [@bib55], the above spectroscopic data suggested that **1** was an unusual indole alkaloid *β*-[d]{.smallcaps}-glucoside containing the 1′-(4″-hydroxy-3″,5″-dimethoxyphenyl)ethyl moiety[@bib56]. The structure was further elucidated by 2D NMR data analysis. In the ^1^H--^1^H COSY spectrum of **1**, homonuclear vicinal coupling cross-peaks of H-4/H-5/H-6/H-7 ([Fig. 2](#fig2){ref-type="fig"}), combined with the chemical shifts and coupling constants of these protons, confirmed the presence of the *ortho*-disubstituted benzene ring. In the HMBC spectrum, two and three-bond correlations from H-7 to C-3a and C-5; from H-4 to C-7a and C-6; from H-5 to C-7 and C-3a; from H-6 to C-4 and C-7a; and from H-2 to C-3, C-7a, and C-3a; along with their chemical shifts, proved that there was a 3-substituted indole moiety in **1**. The HMBC correlations from H-1‴ to C-3, combined with the ^1^H--^1^H COSY correlations of H-1‴/H-2‴/H-3‴/H-4‴/H-5‴/H~2~-6‴ ([Fig. 2](#fig2){ref-type="fig"}) as well as chemical shifts of these proton and carbon resonances, located a *β*-[d]{.smallcaps}-glucopyranosyloxy unit at the C-3 of the indole moiety. In addition, the HMBC correlations from H-1′ to C-2, C-2′, C-2″/6″, and C-7a; from H~3~-2′ to C-1′ and C-1″; along with the ^1^H--^1^H COSY cross-peaks between H-1′ and H~3~-2′ and their chemical shifts, located the 1′-(4″-hydroxy-3″,5″-dimethoxyphenyl)ethyl moiety at the N atom of the indole moiety. Accordingly, the planar structure of **1** was elucidated as shown. The CD (circular dichroism) spectrum of **1** displayed two positive Cotton effects at 206 and 292 nm and a negative Cotton effect at 234 nm, arising from overlapped transitions of the indole and benzene chromophores[@bib57] in the molecule. The 1′*S* configuration of **1** was assigned by calculations of ECD (electronic circular dichroism) spectra using the time-dependent density functional theory (TDDFT) method[@bib58]. The calculated ECD spectrum of **1** was in well agreement with the experimental CD spectrum ([Supporting Information Fig. S3](#appsec1){ref-type="fn"}). Therefore, the structure of compound **1** was determined and named isatidifoliumoside A.Figure 2Main ^1^H--^1^H COSY (thick lines) and three-bond HMBC (arrows, from ^1^H to ^13^C) correlations of compounds **1**--**7**.Figure 2

Compound **2**, white amorphous powder {$\left\lbrack \alpha \right\rbrack_{\text{D}}^{20}$ --50.5 (*c* 0.1, MeOH)}, was separated by chiral HPLC from a mixture of **1** and **2** with peak integrations in around 1:1 ratio ([Supporting Information Fig. S26](#appsec1){ref-type="fn"}). Comparison of the NMR spectroscopic data of **2** and **1** ([Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}) demonstrated that the C-2 resonance in **2** was shielded by Δ*δ*~C~ −0.2 ppm, while the other proton and carbon resonances were shifted by Δ*δ*~H~≤±0.01 and Δ*δ*~C~≤±0.1 ppm, respectively. This suggested that **2** was the 1′-epimer of **1**, which was confirmed by HR-ESI-MS and 2D NMR data analysis ([Fig. 2](#fig2){ref-type="fig"}) as well as by the specific rotation and CEs ([Fig. 3](#fig3){ref-type="fig"}) of **2**. Especially, the experimental CD and calculated ECD spectra of **2** were consistent with each other ([Fig. S3](#appsec1){ref-type="fn"}). Thus, the structure of compound **2** was determined and named epiisatidifoliumoside A.Figure 3The overlaid experimental CD spectra of **1**−**7**.Figure 3

Compound **3**, a white amorphous powder with $\left\lbrack \alpha \right\rbrack_{\text{D}}^{20}$ +4.7 (*c* 0.1, MeOH), is another isomer of **1** as indicated by (+)-HR-ESI-MS, NMR, and IR spectroscopic data. Comparison of the NMR data of **3** with those of **1** ([Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}) indicated that the two compounds mainly differed in substitution of the methine unit (C-2) in **1** by a quaternary carbon (*δ*~C~ 133.0) in **3**. In addition, as compared with those of **1**, the H-1′ and C-1′ resonances in **3** were shielded by Δ*δ*~H~ −0.86 and Δ*δ*~C~ −20.4 ppm. This suggested that the 1′-(4″-hydroxy-3″,5″-dimethoxyphenyl)ethyl moiety at the N atom in **1** was migrated to C-2 in **3**. The suggestion was verified by 2D NMR data analysis ([Fig. 2](#fig2){ref-type="fig"}). Especially the HMBC correlation from H-1‴ to C-3, from H-1′ to C-2, C-1″ and C-2″/6″, and from H-2′ to C-2 and C-1″ proved the locations of the *β*-glucopyranosyloxy and 1′-(4″-hydroxy-3″,5″-dimethoxyphenyl)ethyl moieties at C-3 and C-2 in **3**, respectively. Using the aforementioned protocol, the [d]{.smallcaps}-configuration of *β*-glucopyranosyl in **3** was verified. Comparison of the experimental CD and calculated ECD spectra supported the 1′*R* configuration of **3** ([Supporting Information Fig. S6](#appsec1){ref-type="fn"}). Therefore, the structure of compound **3** was determined and named isatidifoliumoside B.

Compound **4**, a white amorphous powder with $\left\lbrack \alpha \right\rbrack_{\text{D}}^{20}$ --22.4 (*c* 0.1, MeOH), showed similar spectroscopic data as those of **3**. Comparison of the NMR spectroscopic data of the two compounds ([Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}) demonstrated that H-2″/6″, H-6‴a and H-6‴b, and C-2 in **4** were shielded by Δ*δ*~H~ −0.07, −0.16 and −0.07, and Δ*δ*~C~ −0.8 ppm, respectively, whereas C-3 was deshielded by Δ*δ*~C~ +0.8 ppm. This, together with nearly opposite CEs of the two compounds ([Fig. 3](#fig3){ref-type="fig"}), suggested that **4** was 1′-epimer of **3**, which was further confirmed by 2D NMR data analysis ([Fig. 2](#fig2){ref-type="fig"}) as well as by comparison of the experimental CD and calculated ECD spectra of **4** ([Fig. S6](#appsec1){ref-type="fn"}). Thus, the structure of compound **4** was determined and named epiisatidifoliumoside B.

Compound **5**, a white amorphous powder with $\left\lbrack \alpha \right\rbrack_{\text{D}}^{20}$ +8.6 (*c* 0.1, MeOH), is the isomer of **3** and **4** having a different sugar unit, as indicated by spectroscopic data and confirmed by 2D NMR data analysis. Especially, in the HMBC spectrum, correlations from H-1‴ to C-3 and from H-2′ to C-2 ([Fig. 2](#fig2){ref-type="fig"}) confirmed that the sugar and 1′-(4″-hydroxy-3″,5″-dimethoxyphenyl)ethyl units located at C-3 and C-2 of the indole nucleus in **5**, respectively. In the ^1^H NMR spectrum of **5**, the coupling constants (*J*~1‴,2‴~ = 7.8 Hz, *J*~2‴,3‴~ = *J*~3‴,4‴~ = 3.0 Hz, and *J*~4‴,5‴~ = 9.6 Hz) indicated that the sugar unit was *β*-allopyranosyl only differing from *β*-glycopyranosyl in the 3‴-configuration. This deduction was proved by enzymatic hydrolysis of **5** with snailase. The sugar isolated from the hydrolysate of **5** exhibited retention factor (*R*~f~) on TLC, specific rotation {$\left\lbrack \alpha \right\rbrack_{\text{D}}^{20}$ +12.0 (*c* 0.07, H~2~O)} (see Experimental Section), and ^1^H NMR spectroscopic data completely identical to those of an authentic [d]{.smallcaps}-allopyranose (Supporting Information [Figs. S122 and S125](#appsec1){ref-type="fn"}). Similarity of the CD curves between **5** and **3** ([Fig. 3](#fig3){ref-type="fig"}) demonstrated that the two compounds possessed the same 1′*R* configuration, which was supported by comparison of the experimental CD and the calculated ECD spectra of **5** ([Supporting Information Fig. S9](#appsec1){ref-type="fn"}). Therefore, the structure of compound **5** was determined and named isatidifoliumoside C.

Compound **6** was obtained as a white amorphous powder with $\left\lbrack \alpha \right\rbrack_{\text{D}}^{20}$ −35.6 (*c* 0.1, MeOH). Comparison of the NMR spectroscopic data of **6** and **5** ([Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}) demonstrated that the H-6‴a and H-6‴b, and C-2 resonances in **6** were shielded by Δ*δ*~H~ −0.16, −0.07 and Δ*δ*~C~ −0.8 ppm, respectively, whereas the C-3 resonance was deshielded by Δ*δ*~C~ +0.8 ppm. The differences suggested that **6** is the 1′*-*epimer of **5**, which was supported by the reverse CEs in the CD spectrum of **6** as compared with that of **5** ([Fig. 3](#fig3){ref-type="fig"}). The elucidation was verified by 2D NMR data analysis ([Fig. 2](#fig2){ref-type="fig"}) as well as by consistence of the experimental CD and calculated ECD spectra of **6** ([Fig. S9](#appsec1){ref-type="fn"}). Thus, the structure of compound **6** was determined and named epiisatidifoliumoside C.

Compound **7** was obtained as a white amorphous powder with $\left\lbrack \alpha \right\rbrack_{\text{D}}^{20}$ --67.5 (*c* 0.1, MeOH). The spectroscopic data demonstrated that **7** was one more isomer of **3** and **4** having the same *β*-[d]{.smallcaps}-glucopyranosyl unit. The presence of *β*-[d]{.smallcaps}-glucopyranosyl in **7** was verified by enzymatic hydrolysis (see Experimental Section). As compared, the NMR spectroscopic data ([Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}) indicated replacement of the 2,3-disubstited indole nucleus in **3** and **4** by a 3,4-disubstited indole in **7**. This was confirmed by 2D NMR spectroscopic data analysis of **7** ([Fig. 2](#fig2){ref-type="fig"}). In particular, the HMBC spectrum of **7** showed the correlations from H-1′ to C-1″, C-2, C-3, C-3a, and C-2″/6″; from H-1‴ to C-4; and from H~3~-2′ to C-1″ and C-3. These correlations revealed that the *β*-[d]{.smallcaps}-glucopyranosyloxy and 1′-(4″-hydroxy-3″,5″-dimethoxyphenyl)ethyl units substituted at the C-4 and C-3 of the indole nucleus in **7**, respectively. The 1′*S* configuration of **7** was assigned by consistence of the experimental CD and calculated ECD spectra ([Supporting Information Fig. S12](#appsec1){ref-type="fn"}). Therefore, the structure of **7** was determined and named isatidifoliumoside D.

Adducting and deducting analysis of the specific rotation data of the three pairs of epimers showed that the glycosidic indole moieties contributed the $\left\lbrack \alpha \right\rbrack_{\text{D}}^{20}$ values of −37.1, −8.9, and −13.4 to **1**/**2**, **3**/**4**, and **5**/**6**, respectively, while the (1′*S*)-/(1′*R*)-1′- and (1′*R*)-/(1′*S*)-1′-(4″-hydroxy-3″,5″-dimethoxyphenyl)ethyl unit contributed +/−13.4 to **1**/**2** and +/−13.5 and +/−22.0 to **3**/**4** and **5**/**6**. These data revealed that the contributions of the 1′-(4″-hydroxy-3″,5″-dimethoxyphenyl)ethyl unit to the specific rotation data depended upon the C-1′ configuration as well as the location of the unit at the glycosidic indole nucleus. At the N-1 atom, the (1′*S*)-1′-(4″-hydroxy-3″,5″-dimethoxyphenyl)ethyl had the positive contribution (**1**), and at C-2 (**4** and **6**) the negative. In contrast, (1′*R*)-1′-(4″-hydroxy-3″,5″-dimethoxyphenyl)ethyl at N-1 (**2**) had the negative contribution, and at C-2 (**3** and **5**) the positive. As compared with those of **1**, **2**, **4**, and **6**, the specific rotation value of **7** suggested that the (1′*S*)-1′-(4″-hydroxy-3″,5″-dimethoxyphenyl)ethyl unit at C-3 had the negative contribution though the 1′*R* epimer of **7** was not obtained in this study. In addition, comparison of the CD spectra of **1**--**6** showed that signs of the CEs were dominated by the C-1′ configuration and location of the 1′-(4″-hydroxy-3″,5″-dimethoxyphenyl)ethyl unit ([Fig. 3](#fig3){ref-type="fig"}). The CD spectra of **1**--**6** display three CEs around 210, 236, and 288 nm, arising from the overlapped ^1^*B*~a~/^1^*L*~a~, ^1^*B*~b~/^1^*L*~b~, and ^1^*L*~b~/transitions of the substituted indole/benzene chromophores[@bib57], respectively. The (1′*S*)-1′-(4″-hydroxy-3″,5″-dimethoxyphenyl)ethyl unit at the N atom (**1**) dominated the positive ^1^*B*~a~/^1^*L*~a~ (210 nm) and ^1^*L*~b~/(293 nm) and negative ^1^*B*~b~/^1^*L*~b~ (236 nm) CEs, whereas at C-2 (**4** and **6**) it gave the corresponding reverse CEs. Meanwhile, the (1′*R*)-1′-(4″-hydroxy-3″,5″-dimethoxyphenyl)ethyl unit at the N atom (**2**) dominated the negative ^1^*B*~a~/^1^*L*~a~ and ^1^*L*~b~/and positive ^1^*B*~b~/^1^*L*~b~ CEs, and at C-2 (**3** and **5**) the positive ^1^*B*~a~/^1^*L*~a~ and ^1^*L*~b~/and negative^1^*B*~b~/^1^*L*~b~ CEs. Adduction of the CD data between the epimeric pairs indicated that the glycosidic indole moieties in **1**--**6** had the relatively weak contributions to the ^1^*B*~a~/^1^*L*~a~ (positive) and ^1^*L*~b~ (negative) CEs. This was supported by high consistence of the experimental CD and calculated ECD spectra of **1**--**6** ([Figs. S3, S6, and S9](#appsec1){ref-type="fn"}) as well as by the calculated ECD spectra of aglycones **1a**--**6a** ([Supporting Information Figs. S14, S16, and S17](#appsec1){ref-type="fn"}) and the proposed biogenetic precursors **8** and **9** ([Supporting Information Figs. S23−25](#appsec1){ref-type="fn"}). The CD spectrum of **7** exhibited the positive ^1^*B*~a~/^1^*L*~a~ (200 nm) and ^1^*L*~b~/(274 nm) and negative ^1^*B*~b~/^1^*L*~b~ (225 nm) CEs. As compared with those of **3** and **4**, wavelengths of the CE maximums of **7** were blue-shifted by Δ*λ*~max~ 10 nm (see [Fig. 3](#fig3){ref-type="fig"}), which would be due to the location change of the substituents at the indole ring. Further comparison of the experimental CD and calculated ECD spectra supported that the 1′*S* configuration dominated the CEs of **7**. This was also supported by the calculated ECD spectra of the aglycone **7a** and the proposed biogenetic precursor **10** ([Supporting Information Figs. S19 and S25](#appsec1){ref-type="fn"}).

Based on the above analysis, two preliminary rules to assign location and configuration of the *β*-[d]{.smallcaps}-glucopyranosyloxy, *β*-[d]{.smallcaps}-allopyranosyloxy, and 1′-(4″-hydroxy-3″,5″-dimethoxyphenyl)ethyl in these indole glycosides are disclosed: (a) *β*-[d]{.smallcaps}-glucopyranosyloxy at C-3 or C-4 as well as *β*-[d]{.smallcaps}-allopyranosyloxy at C-3 of the indole nucleus have the negative contributions to both the specific rotation ($\left\lbrack \alpha \right\rbrack_{\text{D}}^{20}$\>8.0) and ^1^*B*~b~ CE (230 ± 7 nm); and (b) the (1′*S*)-1′-(phenyl)ethyl units at the N atom or C-3 and the (1′*R*)-1′-(phenyl)ethyl units at C-2 positively contributes to the specific rotation and ^1^*L*~b~/CE (284 ± 10 nm) but negatively to the ^1^*B*~b~/^1^*L*~b~ (230 ± 7 nm) CE, whereas the (1′*R*)-1′-(phenyl)ethyl units at the N atom or C-3 and the (1′*S*)-1′-(phenyl)ethyl units at C-2 negatively contributes to the specific rotation and ^1^*L*~b~/CE (284 ± 10 nm) but positively to the ^1^*B*~b~/^1^*L*~b~ (230 ± 7 nm) CE. The roles simply using the specific rotation and/or CD data may be validated to determination of the location and configuration of other *β*-glycopyranosyloxy and 1′-(phenyl)ethyl units in the related indole glycosides.

Compounds **1**--**7**, together with isatidifoliumindolinones A--D from the same extract[@bib56], represent the first examples of natural products with the novel carbon skeleton derived from coupling between the indole or indolin-3-one and phenylethyl units, especially **1**--**7** are the first glycosidic forms. Based on the molecular architecture, the biosynthetic precursors of **1**--**7** are traced to 1*H*-indol-3-ol glycosides (**8**--**10**) and sinapic acid (**11**), among them **8** was reported from the roots of the plant[@bib42] and **11** from this study. A plausible biosynthetic pathway for **1**--**7** is postulated in [Scheme 1](#sch1){ref-type="fig"}. Decarboxylation of **11** gives an intermediate 2,6-dimethoxy-4-vinylphenol (**12**), which undergoes nucleophilic addition with **8**, **9**, or **10** to generate **1**--**7**. Interestingly, in this plant the epimers occur in the relative ratios of 1:1 for **1**/**2** and 3:2 for **3**/**4** and **5**/**6**, as indicated by chiral HPLC separation ([Supporting Information Figs. S26--28](#appsec1){ref-type="fn"}). This demonstrates that the nucleophilic addition of **12** with **8** to produce **1**/**2** is non-stereoselective, while the addition of **12** with **8** or **9** to give **3**/**4** or **5**/**6** is partially stereoselective. However, the addition of **12** with **10** to yield **7** is fully stereoselective. These facts suggest that location of *β*-[d]{.smallcaps}-glucopyranosyloxy/*β*-[d]{.smallcaps}-allopyranosyloxy and nucleophilic center on the indole nucleus play important roles in stereoselective biosynthesis of **1**--**7**. In addition, **3** and/or **4** is the potential precursors of isatidifoliumindolinones A--D[@bib56] that may be produced by hydrolysis of **3** and/or **4**, followed by successive or simultaneous oxidation and methylation/methoxylation (not shown in [Scheme 1](#sch1){ref-type="fig"}).Scheme 1Proposed biosynthetic pathways of **1**--**7**.Scheme 1

In the preliminary *in vitro* assays, compounds **3** and **4** as well as their mixture in 1:1 showed inhibitory activity against the K^+^ channel KCNQ2 in CHO cells with IC~50~ 19.15, 11.57, and 13.27 μmol/L, respectively (the positive control ML252, IC~50~ 0.27 ± 0.2 μmol/L), indicating that **4** with the 1′*S* configuration is relatively more active than **3** with the 1′*R* configuration. However, in this assay **1**, **2**, and **5**--**7** were inactive at a concentration of 10^−4^ mol/L. In addition, the mixture of **5** and **6** in the 3:2 ratio exhibited antiviral activity against influenza virus H1N1 PR8 with IC~50~ 64.7 μmol/L (the positive control ribavirin, IC~50~ 54.3 μmol/L), while the individual epimers **5** and **6** were inactive (10^−4^ mol/L). This suggested that the epimers had a synergistic effect against influenza virus H1N1 PR8. The results provide preliminary clues for activity--structure relationships of these indole glycosides. For KCNQ2 inhibition, *β*-[d]{.smallcaps}-glucopyranosyloxy at C-3 is required while the 1′*S* configuration may increase activity, and for anti-influenza virus H1N1 PR8, *β*-[d]{.smallcaps}-allopyranosyloxy at C-3 and a synergistic effect of the 1′*S* and 1′*R* configurations play roles.

3. Conclusions {#sec3}
==============

Seven indole alkaloid glycosides containing the 1′-(4″-hydroxy-3″,5″-dimethoxyphenyl)ethyl unit (**1**--**7**) were isolated from the *I. indigotica* leaves (da qing ye) decoction. The aglycones, together with that of the stereoisomer isatidifoliumindolinones A−D from the same decoction[@bib56], represent a novel group of the indole alkaloid natural products. Based on structure-specific rotation/Cotton effect analysis of **1**--**7**, two preliminary roles are proposed for assignment of the location and configuration of the *β*-glycopyranosyloxy and 1′-(phenyl)ethyl units in the indole alkaloid glycosides. Compounds **5** and **6** are the first indole alkaloid *β*-[d]{.smallcaps}-allopyranosides. Especially the two allopyranoside epimers showed the synergistic effect against influenza virus H1N1 PR8, representing the novel antiviral constituents from the decoction of *I. indigotica* leaves[@bib9], [@bib23], [@bib59] that support clinical application of the herbal medicine and the theory of multiple active components of traditional Chinese medicine.

4. Experimental {#sec4}
===============

4.1. General experimental procedures {#sec4.1}
------------------------------------

See [Supporting Information](#appsec1){ref-type="fn"}.

4.2. Plant material {#sec4.2}
-------------------

See Ref.[@bib56].

4.3. Extraction and isolation {#sec4.3}
-----------------------------

For preliminary extraction and isolation, see Ref. 56. Subfraction B2-4-1-21 (1.5 g) was chromatographed over silica gel, eluting with CHCl~2~/MeOH (15:1), to give B2-4-1-21-1−B2-4-1-21-10, of which B2-4-1-21-8 (60 mg) was further separated by RP-HPLC (25% acetonitrile, 3.0 mL/min) to afford a mixture (20 mg, *t*~R~ = 35.1 min). The mixture was separated by chiral HPLC with a Chiralpak AD-H column (250 mm × 10 mm) using a mobile phase of EtOH/*n*-hexane (27:73, flow rate 1.0 mL/min) to yield **5** (5.0 mg, *t*~R~ = 34.1 min) and **6** (3.5 mg, *t*~R~ = 37.8 min). Subfraction B2-4-2-9 (500 mg) was further fractionated by CC over HW-40C (MeOH) to yield B2-4-2-9-1−B2-4-2-9-4, of which subfraction B2-4-2-9-2 (16 mg) was separated by RP-HPLC (40% MeOH, 3.0 mL/min) afforded **7** (4.0 mg, *t*~R~ = 25.0 min). Fraction B2-4-2 (20 g) was fractionated by CC over RP (C18) silica gel (460 mm × 36 mm, 150 g) eluting with a gradient of increasing MeOH concentration (0%--100%) in H~2~O to yield B2-4-2-1−B2-4-2-28. Purification of B2-4-2-25 (30 mg) by RP-HPLC (8% acetonitrile, 3.0 mL/min) afforded a mixture (12 mg, *t*~R~ = 22.2 min), which was further separated by chiral HPLC with a Chiralpak AD-H column (250 mm × 10 mm, EtOH/*n*-hexane 3:7, flow rate 1.5 mL/min) to obtain **1** (4.0 mg, *t*~R~ = 22.3 min) and **2** (3.5 mg, *t*~R~ = 37.2 min). Separation of B2-4-2-19 (300 mg) by RP-HPLC (30% MeOH, 3.0 mL/min) afforded the mixture (10 mg, *t*~R~ = 77.0 min), which were isolated by chiral HPLC with a Chiralpak AD-H column (250 mm × 10 mm, EtOH/*n*-hexane 1:3, flow rate 2.5 mL/min) to obtain **3** (4.5 mg, *t*~R~ = 30.6 min) and **4** (3.0 mg, *t*~R~ = 35.7 min).

### 4.3.1. Isatidifoliumoside A (**1**) {#sec4.3.1}

White amorphous powder; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{20}$ --23.7 (*c* 0.1, MeOH); UV (MeOH) *λ*~max~ (log *ε*) 207 (4.59), 228 (4.40), 281 (3.64) nm; CD (MeOH) *λ*~max~ (Δ*ε*) 206 (+39.5), 234 (−28.1), 292 (+3.53) nm; IR *ν*~max~ 3403, 2935, 1613, 1554, 1519, 1460, 1427, 1361, 1331, 1225, 1157, 1115, 911, 836, 800, 743, 670, 615 cm^−1^; see ^1^H NMR (CD~3~OD, 600 MHz) data in [Table 1](#tbl1){ref-type="table"}; See ^13^C NMR (CD~3~OD, 150 MHz) data in [Table 2](#tbl2){ref-type="table"}; (+)-ESI-MS *m/z* 476 \[M+H\]^+^, 498 \[M+Na\]^+^; (−)-ESI-MS *m/z* 474 \[M--H\]^−^; (+)-HR-ESI-MS *m/z* 498.1746 \[M+Na\]^+^ (Calcd. for C~24~H~29~NO~9~Na, 498.1735).

### 4.3.2. Episatidifoliumoside A (**2**) {#sec4.3.2}

White amorphous powder; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{20}$ --50.5 (*c* 0.1, MeOH); UV (MeOH) *λ*~max~ (log *ε*) 207 (4.74), 228 (4.54), 281 (3.84) nm; CD (MeOH) *λ*~max~ (Δ*ε*) 210 (−26.9), 236 (+22.1), 293 (−3.73) nm; IR *ν*~max~ 3402, 2934, 1613, 1554, 1519, 1460, 1427, 1361, 1331, 1226, 1157, 1116, 911, 836, 800, 743, 670, 614 cm^−1^; see ^1^H NMR (CD~3~OD, 600 MHz) data in [Table 1](#tbl1){ref-type="table"}; see ^13^C NMR (CD~3~OD, 150 MHz) data in [Table 2](#tbl2){ref-type="table"}; (+)-ESI-MS *m/z* 498 \[M+Na\]^+^; (−)-ESI-MS *m/z* 474 \[M--H\]^−^; (+)-HR-ESI-MS *m/z* 498.1739 \[M+Na\]^+^ (Calcd. for C~24~H~29~NO~9~Na, 498.1735).

### 4.3.3. Isatidifoliumoside B (**3**) {#sec4.3.3}

White amorphous powder; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{20}$ +4.7 (*c* 0.1, MeOH); UV (MeOH) *λ*~max~ (log *ε*) 206 (4.67), 227 (4.40), 283 (3.85) nm; CD *λ*~max~ (Δ*ε*) 210 (+13.9), 235 (−29.5), 284 (+5.78) nm; IR *ν*~max~ 3359, 2971, 2932, 1701, 1617, 1518, 1459, 1427, 1326, 1220, 1157, 1115, 1072, 941, 901, 838, 797, 750, 588 cm^−1^; see ^1^H NMR (CD~3~OD, 600 MHz) data in [Table 1](#tbl1){ref-type="table"}; see ^13^C NMR (CD~3~OD, 150 MHz) data in [Table 2](#tbl2){ref-type="table"}; (+)-ESI-MS *m/z* 498 \[M+Na\]^+^; (−)-ESI-MS *m/z* 474 \[M--H\]^−^; (+)-HR-ESI-MS *m/z* 476.1922 \[M+H\]^+^ (Calcd. for C~24~H~30~NO~9~, 476.1915).

### 4.3.4. Episatidifoliumoside B (**4**) {#sec4.3.4}

White amorphous powder; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{20}$ --22.4 (*c* 0.1, MeOH); UV (MeOH) *λ*~max~ (log *ε*) 206 (4.51), 226 (4.38), 281 (3.79) nm; CD *λ*~max~ (Δ*ε*) 211 (−10.8), 236 (+22.3), 284 (−4.11) nm; IR *ν*~max~ 3352, 2972, 2931, 1702, 1616, 1518, 1459, 1426, 1326, 1220, 1116, 1075, 1047, 941, 880, 837, 798, 749, 636 cm^−1^; see ^1^H NMR (CD~3~OD, 600 MHz) data in [Table 1](#tbl1){ref-type="table"}; see ^13^C NMR (CD~3~OD, 150 MHz) data in [Table 2](#tbl2){ref-type="table"}; (+)-ESI-MS *m/z* 498 \[M+Na\]^+^; (−)-ESI-MS *m/z* 474 \[M--H\]^−^; (+)-HR-ESI-MS *m/z* 476.1925 \[M+H\]^+^ (Calcd. for C~24~H~30~NO~9~, 476.1915).

### 4.3.5. Isatidifoliumoside C (**5**) {#sec4.3.5}

White amorphous powder; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{20}$ +8.6 (*c* 0.1, MeOH); UV (MeOH) *λ*~max~ (log *ε*) 206 (4.57), 226 (4.55), 282 (4.01) nm; CD *λ*~max~ (Δ*ε*) 210 (+20.7), 236 (−24.8), 285 (+5.24) nm; IR *ν*~max~ 3373, 2932, 1616, 1518, 1459, 1426, 1326, 1218, 1115, 1041, 941, 910, 837, 797, 735, 633 cm^−1^; see ^1^H NMR (CD~3~OD, 600 MHz) data in [Table 1](#tbl1){ref-type="table"}; see ^13^C NMR (CD~3~OD, 150 MHz) data in [Table 2](#tbl2){ref-type="table"}; (+)-ESI-MS *m/z* 498 \[M+Na\]^+^; (+)-HR-ESI-MS *m/z* 476.1929 \[M+H\]^+^ (Calcd. for C~24~H~30~NO~9~, 476.1915).

### 4.3.6. Episatidifoliumoside C (**6**) {#sec4.3.6}

White amorphous powder; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{20}$ --35.6 (*c* 0.1, MeOH); UV (MeOH) *λ*~max~ (log *ε*) 206 (4.62), 227 (4.37), 282 (3.77) nm; CD *λ*~max~ (Δ*ε*) 210 (−13.7), 236 (+18.4), 287 (−3.37) nm; IR *ν*~max~ 3375, 2927, 1966, 1616, 1518, 1459, 1426, 1325, 1218, 1115, 1039, 941, 910, 837, 797, 736 cm^−1^; see ^1^H NMR (CD~3~OD, 600 MHz) data in [Table 1](#tbl1){ref-type="table"}; see ^13^C NMR (CD~3~OD, 150 MHz) data in [Table 2](#tbl2){ref-type="table"}; (+)-ESI-MS *m/z* 498 \[M+Na\]^+^; (−)-ESI-MS *m/z* 474 \[M--H\]^−^; (+)-HR-ESI-MS *m/z* 476.1928 \[M+H\]^+^ (Calcd. for C~24~H~30~NO~9~, 476.1915).

### 4.3.7. Isatidifoliumoside D (**7**) {#sec4.3.7}

White amorphous powder; $\left\lbrack \alpha \right\rbrack_{\text{D}}^{20}$ --67.5 (*c* 0.1, MeOH); UV (MeOH) *λ*~max~ (log *ε*) 206 (4.68), 222 (4.62), 271 (3.93) nm; CD *λ*~max~ (Δ*ε*) 225 (−28.1), 274 (+5.33) nm; IR *ν*~max~ 3370, 2968, 2934, 1677, 1617, 1514, 1460, 1426, 1356, 1325, 1229, 1079, 913, 838, 800, 743, 655 cm^−1^; see ^1^H NMR (CD~3~OD, 600 MHz) data in [Table 1](#tbl1){ref-type="table"}; see ^13^C NMR (CD~3~OD, 150 MHz) data in [Table 2](#tbl2){ref-type="table"}; (+)-ESI-MS *m/z* 498 \[M+Na\]^+^; (−)-ESI-MS *m/z* 474 \[M--H\]^−^; (+)-HR-ESI-MS *m/z* 498.1726 \[M+Na\]^+^ (Calcd. for C~24~H~29~NO~9~Na 498.1735).

### 4.3.8. Enzymatic hydrolysis of **1**, **3**, **5**, and **7** {#sec4.3.8}

Compounds **1**, **3**, **5**, and **7** (2.0--3.0 mg) were separately hydrolyzed in H~2~O (5 mL) with snailase (5.0 mg, CODE S0100, Beijing Biodee Biotech Co., Ltd., Beijing, China) at 37 °C for 24 h. The hydrolysate was evaporated under reduced pressure, then chromatographed over silica gel eluting with CH~3~CN/H~2~O (8:1), to yield sugar. The sugar (0.8--1.2 mg) from the hydrolysates of **1**, **3**, and **7** gave retention factor (*R*~f~ ∼0.41) on TLC (CH~2~Cl~2~/MeOH/H~2~O, 7:3.5:1), $\left\lbrack \alpha \right\rbrack_{\text{D}}^{20}$ +36.5--+40.2 (*c* 0.06--0.08, H~2~O), and ^1^H NMR (D~2~O, 600 MHz) data, consistent with those of the authentic [d]{.smallcaps}-glucose ([Figs. S120, S121, S123, and S124](#appsec1){ref-type="fn"}). The sugar (0.7 mg) from the hydrolysate of **5** gave retention factor (*R*~f~ ∼0.47) on TLC (CH~2~Cl~2~/MeOH/H~2~O, 7:3.5:1), $\left\lbrack \alpha \right\rbrack_{\text{D}}^{20}$ +12.0 (*c* 0.07, H~2~O), and ^1^H NMR (D~2~O, 600 MHz) data, consistent with those of the authentic [d]{.smallcaps}-allose ([Figs. S122 and S125](#appsec1){ref-type="fn"}).

### 4.3.9. ECD calculations of **1**--**10** and aglycones **1a**−**7a** {#sec4.3.9}

For details, see [Supporting Information](#appsec1){ref-type="fn"}. Briefly, conformational analysis was conducted by Monte Carlo searching with the MMFF94 molecular mechanics force field using the Molecular Operating Environment (MOE) software for **1**--**6** and Gaussian 16 program package for **7**, **1a**−**7a**, and **8**--**10**. The lowest-energy conformers having relative energies within 3 kcal/mol were optimized with the Gaussian 09 or Gaussian 16 program. Subsequently, the conformers were re-optimized using DFT at the B3LYP/6-31 + G (d, p) level for **1**--**7** and at APFD/6-31 + G (d, p) for **8--10** and aglycones **1a**−**7a**, with the solvent effects considered using the dielectric constant of MeOH (*ε* = 32.6) *via* conductor-like polarizable continuum model (CPCM). The energies, oscillator strengths, and rotational strengths of the excitations were calculated using the TDDFT methodology at the B3LYP/6--311++G (2d, 2p) level in vacuum for **1**--**7** and at APFD/6-311 + G (2d, p) for **8--10** and aglycones **1a**−**7a**. The re-optimized conformers showed relative Gibbs free energies (Δ*G*) under 3 kcal/mol were used for ECD spectra simulation. The ECD spectra were simulated by the Gaussian function (*σ* = 0.28 eV). To obtain the final spectra, the simulated spectra of the lowest energy conformers were averaged on the basis of the Boltzmann distribution theory and their relative Gibbs free energy (Δ*G*).

Appendix A. Supplementary data {#appsec3}
==============================

The following is the supplementary data to this article:Multimedia component 1Multimedia component 1
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[^1]: Data (*δ*~H~) were measured for **1**--**7** at 600 MHz. Coupling constants (*J*) in Hz are given in parentheses. The assignments were based on DEPT, ^1^H--^1^H COSY, HSQC, and HMBC experiments.

[^2]: Data (*δ*~C~) were measured in for **1**--**7** at 150 MHz. The assignments were based on DEPT, ^1^H--^1^H COSY, HSQC, and HMBC experiments.
